

**University of Texas Health Science Center at San Antonio  
Institutional Biosafety Committee (IBC)  
Microsoft Teams MINUTES OF MEETING  
November 11, 2025**

**Members attending the meeting:**; Burgin, Tiffani; Chatterjee, Bandana; Chen, Ching-Kang Jason; Chen, Chun-Liang; Dell, Shelbie; Ginsburg, Brett;; Martinez-Sobrido, Luis; Mishra, Bibhuti; Paukert, Martin; Prewit, Egle; Salamango, Daniel; Shiio, Yuzuru; Vogel, Kristine; Wiederhold, Nathan; Xiang, Yan; Yeh, Chih-Ko; Bloodworth, Rebecca; Macias, Dorothy (alternate for Cerecero, Jennifer - voting)

**Guests Present:** Rincon, Erica; Barlett, Emily; Vasquez, Rebecca.

**Absent members:** Bieniek, Kevin; Cerecero, Jennifer; Gauduin, Marie Claire; Gould, Georgianna.

**1. Panel Chair Announcement**

The meeting was called to order at 11:01 a.m. by the IBC Chair, Dr. Yan Xiang.

**2. Confidentiality of Panel Proceedings and Conflict of Interest**

The members of the panel and the persons employed by the panel shall maintain the confidentiality of the panel's proceedings unless such information is already made available to the public. The Parties shall maintain the confidentiality of the panel's hearings, deliberations, and initial report, and all written submissions to, and communications with, the panel.

Board Members will be reminded of their responsibility to declare any conflicts of interest prior to the discussion of an agenda item. Members will be reminded that in the event they have a conflict of interest (e.g. a member of the research team or is supervised by a member of the research team), the Member with a conflict may be in the meeting room to provide information requested by the IBC but will be asked to leave the meeting room before the final discussion and voting on the protocol with which the IBC Member has a conflict.

**3. Approval of minutes from the previous meeting**

The Committee approved the minutes as written from the October 14, 2025, IBC meeting.

**Approved** (17 voted to approve, 0 opposed, 0 abstained)

**4. Review of Approved Protocols-** The spreadsheet of FY2026 approved protocols will be sent out for review in December 2025.

**5. Old Business –**

**6. Educational Items – None**

**7. Occupational Medicine-** As of November 1, 2025, there were 8 needlesticks, five of which were by students, two by MSRH staff, and one by UT staff. There was one Bordetella pertussis exposure by a UT staff member. There were four exposures of TB, two were by students, and the other two were by UT staff. There was a chemical exposure by an MSRH staff member. There was a shoulder injury by an MSRH staff

member.

## 8. Other – None

## 9. Review of EHS Assistant-

Review any issues with the EH&S Assistant program.

## 10. Meeting Reminder

The next meeting will be held on December 09, 2025.

### Protocols for Review

#### 11. Presentation, Discussion, and Voting on an Initial Protocol:

**Protocol ID:** 0000020972

**Principal Investigator:** Banerjee, Swati; Cellular & Integrative Physiology

**Title:** Molecular mechanisms of Tubulin polymerization promoting protein in Mitochondrial function and Neuronal survival.

**Review Type:** Full Committee Review

**Form Type:** Initial

**Approved** (17 voted to approve, 0 opposed, 0 abstained)

Initial application to work with post-mortem human brain tissues at BSL-2 containment.

*Protocol does not include the use of recombinant DNA.*

This protocol was approved as written.

*NIH Guidelines:*

*Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C—1*

#### 12. Presentation, Discussion, and Voting on an Amendment Protocol:

**Protocol ID:** 0000021060

**Principal Investigator:** Lawrenson-Gayther, Kate; Obstetrics/Gynecology

**Title:** N/A

**Review Type:** Full Review

**Form Type:** Amendment

**Approved** (17 voted to approve, 0 opposed, 0 abstained)

Amendment application to work with Sleeping beauty, plasmids (pT3-EF1A-m-tert, SP1-SB100X, pBABE-hygro CDK4 R24C, pBABE-puro SV40, LTHPY-16 E6/E7), and vector FgH1tUTG\_mup53\_Ex5 at BSL-2 containment.

*Protocol does include the use of recombinant DNA.*

This protocol was approved as written

*NIH Guidelines:*

*Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1*

*Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1*

*Use of or the cloning of genes from, or into a Risk Group 2, 3, 4 or restricted agent. III-D-1, 2*

*Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1*

*Cloning and vector construction in bacteria and yeasts. III-E, III-F*

*Use of recombinant or synthetic nucleic acid molecules for detection purposes (e.g. probes) III-F*

*Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F*

*Administration of recombinant or synthetic nucleic acid molecules into animals III-D-4*

*Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3*

*Experiments involving transgenic/knockout animals requiring ABSL-2 and above containment. III-D-4*

**13. Presentation, Discussion, and Voting on a Renewal Protocol:**

**Protocol ID:** 0000020775

**Principal Investigator:** Gould, Georgianna; Cellular & Integrative Physiology

**Title:** N/A

**Review Type:** Full Review

**Form Type:** Renewal

**Approved** (17 voted to approve, 0 opposed, 0 abstained)

Renewal application to work with mouse brain tissue at BSL-1 containment.

*Protocol does not include the use of recombinant DNA.*

This protocol was approved as written.

*NIH Guidelines:*

*Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3*

**14. Presentation, Discussion, and Voting on an Initial Protocol:**

**Protocol ID:** 0000020931

**Principal Investigator:** Simovic, Milomir; Surgery Department

**Title:** Development and validation of innate immunome-targeted therapy to create a pro-survival and organ-protective phenotype after hemorrhage at the point of injury (PR221632)

**Review Type:** Full Review

**Form Type:** Initial

**Approved** (17 voted to approve, 0 opposed, 0 abstained)

Initial application to work with *Staphylococcus aureus* S45F9, pig blood, and pig tissues at a BSL-2 containment.

In vivo

Work with *Staphylococcus aureus* S45F9 in pigs at ABSL-2 containment.

IACUC# IPROTO202500000103

*Protocol does not include the use of recombinant DNA.*

This protocol was with clarifications.

1. The committee requested clarification on animal transportation.
2. The committee requested clarification on animal housing.
3. The committee requested additional clarification on where the bacteria will be stored.
4. The committee requested additional information on sample transportation.

*NIH Guidelines:*

*Experiments involving transgenic/knockout animals requiring ABSL-2 and above containment. III-D-4*

## **15. Presentation, Discussion, and Voting on a Renewal Protocol:**

**Protocol ID:** 0000020820

**Principal Investigator:** Mahadevan, Daruka; Mays Cancer Center

**Title:** N/A

**Review Type:** Full Review

**Form Type:** Rrenewal

**Approved** (17 voted to approve, 0 opposed, 0 abstained)

Renewal application, to work with replication-incompetent defective Lentivirus, human cell lines (293T, BXPC-3, A549, cancer cell lines, Capan-1, Capan-2, DU145, DB, HCT-116, HEK293T, HELA, HH, HL-60, Jurkat, LNCAP, K562, Karpas-229, Lymphoma cell lines, MCF-7, MDA-MB435, MDA-MB231, NIH3T3, OCI-LY10, PANC-1, PC3, Prostate cancer, RL, RPMI8226, RPMI8226/DOX, SUP-TI, VCaP, Lung Cancer cell lines, Glioma, Breast Cancer Cell lines), and lentiviral vector at BSL-2 containment.

Work with *E. coli* (lab strains) at BSL-1 containment.

*Protocol does include the use of recombinant DNA.*

This protocol was approved with clarifications.

1. The committee requested additional information and clarification on the projects listed.
2. The committee requested clarification on which cells listed will be utilized in which project.
3. The committee requested clarification on what type of tissue will be shipped.

*NIH Guidelines:**Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1**Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1**Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1**Cloning and vector construction in bacteria and yeasts. III-E, III-F**Use of recombinant or synthetic nucleic acid molecules for detection purposes (e.g. probes) III-F**Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F***16. Presentation, Discussion, and Voting on an Amendment Protocol:****Protocol ID:** 0000021051**Principal Investigator:** Jiang, Jean; Biochemistry & Structural Biology**Title:** Intercellular communication in the eye lens**Review Type:** Full Review**Form Type:** Amendment**Approved** (17 voted to approve, 0 opposed, 0 abstained)


Amendment application to work with Avian retrovirus at BSL-2 containment.

*Protocol does include the use of recombinant DNA.*

This protocol was approved as written.

*NIH Guidelines:**Use of animal cells/cell lines or tissues (e.g. tissue culture research) II-A-3, Appendix C-1**Use of human cell/cell lines or tissues (e.g. Human blood, 293 cell lines, SCF) II-A-3, Appendix C-1**Use of or the cloning of genes from, or into a Risk Group 2, 3, 4 or restricted agent. III-D-1, 2**Use of virus or viruses (experiments involving influenza viruses fall under III-D-7) III-D-3, III-E-1**Cloning and vector construction in bacteria and yeasts. III-E, III-F**Use of recombinant or synthetic nucleic acid molecules for detection purposes (e.g. probes) III-F**Use of recombinant or synthetic nucleic acid molecule in cultured cells. III-E, III-F**Administration of recombinant or synthetic nucleic acid molecules into animals III-D-4**Experiments involving transgenic/knockout animals requiring ABSL-1 containment. III-E-3*

Adjourn: The meeting adjourned at 11:59 A.M.



Dr. Yan Xiang  
Institutional Biosafety Committee Chair  
University of Texas Health San Antonio



Dorothy Macias  
Recorder, Institutional Biosafety Committee  
University of Texas Health San Antonio

dam